Dr. Michael Niederman, MD

Critical Care Medicine New York, NY Male
NPI: 1073675005
Total Payments
$230,582
2024 Payments
$3,460
Companies
22
Transactions
166
Medicare Patients
1,692
Medicare Billing
$237,756

Payment Breakdown by Category

Consulting$96,616 (41.9%)
Other$77,741 (33.7%)
Travel$35,893 (15.6%)
Research$17,325 (7.5%)
Food & Beverage$2,871 (1.2%)
Education$136.32 (0.1%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $96,616 32 41.9%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $47,191 10 20.5%
Travel and Lodging $35,893 50 15.6%
Honoraria $30,550 17 13.2%
Unspecified $17,325 3 7.5%
Food and Beverage $2,871 50 1.2%
Education $136.32 4 0.1%

Payments by Type

General
$213,257
163 transactions
Research
$17,325
3 transactions

Top Paying Companies

Company Total Records Latest Year
Merck Sharp & Dohme LLC $105,826 74 $0 (2024)
PFIZER INC. $27,754 15 $0 (2022)
Fisher Scientific Company L.L.C. $20,834 18 $0 (2023)
Amgen Inc. $17,325 3 $0 (2021)
Dompe US, Inc. $11,050 5 $0 (2021)
Shionogi Inc $10,543 10 $0 (2020)
Gilead Sciences, Inc. $10,394 6 $0 (2022)
DiaSorin Molecular LLC $7,500 1 $0 (2020)
Bayer HealthCare Pharmaceuticals Inc. $5,750 3 $0 (2020)
Accelerate Diagnostics Inc. $4,389 5 $0 (2021)

Payment History by Year

Year Amount Transactions Top Company
2024 $3,460 6 GlaxoSmithKline, LLC. ($2,000)
2023 $19,854 14 Merck Sharp & Dohme LLC ($19,720)
2022 $11,619 7 Merck Sharp & Dohme LLC ($6,975)
2021 $56,599 20 Merck Sharp & Dohme Corporation ($17,463)
2020 $39,578 25 Fisher Scientific Company L.L.C. ($12,662)
2019 $58,070 52 Merck Sharp & Dohme Corporation ($47,383)
2018 $19,505 19 Shionogi Inc ($8,743)
2017 $21,896 23 PFIZER INC. ($15,083)

All Payment Transactions

166 individual payment records from CMS Open Payments — Page 1 of 7

Date Company Product Nature Form Amount Type
10/16/2024 Merck Sharp & Dohme LLC PREVYMIS (Drug), RECARBRIO, ZERBAXA Food and Beverage In-kind items and services $14.88 General
Category: INFECTIOUS DISEASE
09/25/2024 Merck Sharp & Dohme LLC PREVYMIS (Drug), RECARBRIO, ZERBAXA Food and Beverage In-kind items and services $14.37 General
Category: INFECTIOUS DISEASE
08/14/2024 Merck Sharp & Dohme LLC PREVYMIS (Drug), RECARBRIO, ZERBAXA Food and Beverage In-kind items and services $19.84 General
Category: INFECTIOUS DISEASE
05/01/2024 Merck Sharp & Dohme LLC ZERBAXA (Drug), RECARBRIO Food and Beverage In-kind items and services $15.77 General
Category: INFECTIOUS DISEASE
04/17/2024 GlaxoSmithKline, LLC. — Consulting Fee Cash or cash equivalent $2,000.00 General
03/04/2024 Merck Sharp & Dohme LLC — Consulting Fee Cash or cash equivalent $1,395.00 General
10/16/2023 Merck Sharp & Dohme LLC — Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $3,255.00 General
10/16/2023 Merck Sharp & Dohme LLC — Travel and Lodging Cash or cash equivalent $150.00 General
05/01/2023 Merck Sharp & Dohme LLC — Consulting Fee Cash or cash equivalent $2,325.00 General
03/27/2023 Merck Sharp & Dohme LLC — Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $5,580.00 General
03/27/2023 Merck Sharp & Dohme LLC — Travel and Lodging Cash or cash equivalent $150.00 General
03/23/2023 Merck Sharp & Dohme LLC ZERBAXA (Drug), RECARBRIO Travel and Lodging In-kind items and services $116.23 General
Category: INFECTIOUS DISEASE
03/22/2023 Merck Sharp & Dohme LLC ZERBAXA (Drug), RECARBRIO Travel and Lodging In-kind items and services $352.12 General
Category: INFECTIOUS DISEASE
03/21/2023 Merck Sharp & Dohme LLC ZERBAXA (Drug), RECARBRIO Travel and Lodging In-kind items and services $6,908.05 General
Category: INFECTIOUS DISEASE
03/21/2023 Merck Sharp & Dohme LLC ZERBAXA (Drug), RECARBRIO Travel and Lodging In-kind items and services $352.12 General
Category: INFECTIOUS DISEASE
03/21/2023 Merck Sharp & Dohme LLC ZERBAXA (Drug), RECARBRIO Travel and Lodging In-kind items and services $116.23 General
Category: INFECTIOUS DISEASE
03/21/2023 Merck Sharp & Dohme LLC ZERBAXA (Drug), RECARBRIO Food and Beverage In-kind items and services $63.40 General
Category: INFECTIOUS DISEASE
03/20/2023 Merck Sharp & Dohme LLC ZERBAXA (Drug), RECARBRIO Travel and Lodging In-kind items and services $352.12 General
Category: INFECTIOUS DISEASE
02/11/2023 Fisher Scientific Company L.L.C. Procalcitonin (Device) Food and Beverage In-kind items and services $66.88 General
Category: Infectious Disease
02/05/2023 Fisher Scientific Company L.L.C. Procalcitonin (Device) Food and Beverage In-kind items and services $66.87 General
Category: Infectious Disease
12/01/2022 Merck Sharp & Dohme LLC — Consulting Fee Cash or cash equivalent $3,720.00 General
06/24/2022 Merck Sharp & Dohme LLC — Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $3,255.00 General
05/16/2022 Gilead Sciences, Inc. Veklury (Drug) Food and Beverage In-kind items and services $43.78 General
Category: COVID-19
02/08/2022 Gilead Sciences, Inc. Veklury (Drug) Consulting Fee Cash or cash equivalent $850.00 General
Category: COVID-19
02/03/2022 Gilead Sciences, Inc. Veklury (Drug) Consulting Fee Cash or cash equivalent $1,050.00 General
Category: COVID-19
123…7»

Research Studies & Clinical Trials

Study Name Company Amount Records
AMG 407 (OTEZLA) - Ph 3 COVID Consortium Study Amgen Inc. $17,325 3

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 5 496 731 $282,195 $74,787
2022 5 454 670 $223,725 $63,027
2021 8 360 516 $159,890 $51,734
2020 10 382 513 $187,735 $48,208
Total Patients
1,692
Total Services
2,430
Medicare Billing
$237,756
Procedure Codes
28

All Medicare Procedures & Services

28 procedure records from CMS Medicare Utilization — Page 1 of 2

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2023 211 402 $171,050 $45,757 26.8%
99204 New patient office or other outpatient visit, 45-59 minutes Office 2023 106 106 $55,650 $15,104 27.1%
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2023 126 163 $48,975 $12,323 25.2%
99203 New patient office or other outpatient visit, 30-44 minutes Office 2023 13 13 $4,875 $1,208 24.8%
36415 Insertion of needle into vein for collection of blood sample Office 2023 40 47 $1,645 $394.80 24.0%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2022 161 274 $105,060 $29,562 28.1%
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2022 159 249 $66,930 $19,786 29.6%
99204 New patient office or other outpatient visit, 45-59 minutes Office 2022 87 87 $45,675 $12,274 26.9%
99203 New patient office or other outpatient visit, 30-44 minutes Office 2022 12 12 $4,380 $1,262 28.8%
36415 Insertion of needle into vein for collection of blood sample Office 2022 35 48 $1,680 $141.84 8.4%
99214 Established patient outpatient visit, total time 30-39 minutes Office 2021 135 248 $84,320 $28,304 33.6%
99213 Established patient outpatient visit, total time 20-29 minutes Office 2021 81 116 $26,680 $8,698 32.6%
99204 New patient outpatient visit, total time 45-59 minutes Office 2021 47 47 $24,675 $6,897 28.0%
99215 Established patient outpatient visit, total time 40-54 minutes Office 2021 22 24 $10,920 $3,304 30.3%
99205 New patient outpatient visit, total time 60-74 minutes Office 2021 14 14 $9,100 $2,892 31.8%
90662 Vaccine for influenza for injection into muscle, split virus, preservation free Office 2021 19 19 $1,615 $1,175 72.7%
G0008 Administration of influenza virus vaccine Office 2021 20 20 $1,600 $379.81 23.7%
36415 Insertion of needle into vein for collection of blood sample Office 2021 22 28 $980.00 $84.00 8.6%
99214 Established patient office or other outpatient, visit typically 25 minutes Office 2020 127 195 $66,300 $16,851 25.4%
99215 Established patient office or other outpatient, visit typically 40 minutes Office 2020 37 49 $22,295 $6,196 27.8%
99213 Established patient office or other outpatient visit, typically 15 minutes Office 2020 63 82 $18,860 $5,543 29.4%
99291 Critical care delivery critically ill or injured patient, first 30-74 minutes Facility 2020 15 27 $26,595 $5,420 20.4%
99204 New patient office or other outpatient visit, typically 45 minutes Office 2020 37 37 $19,425 $5,222 26.9%
99205 New patient office or other outpatient visit, typically 60 minutes Office 2020 19 19 $12,350 $3,077 24.9%
99232 Subsequent hospital inpatient care, typically 25 minutes per day Facility 2020 27 35 $8,050 $2,278 28.3%
12»

About Dr. Michael Niederman, MD

Dr. Michael Niederman, MD is a Critical Care Medicine healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1073675005.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Niederman, MD has received a total of $230,582 in payments from pharmaceutical and medical device companies, with $3,460 received in 2024. These payments were reported across 166 transactions from 22 companies. The most common payment nature is "Consulting Fee" ($96,616).

As a Medicare-enrolled provider, Niederman has provided services to 1,692 Medicare beneficiaries, totaling 2,430 services with total Medicare billing of $237,756. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.

Practice Information

  • Specialty Critical Care Medicine
  • Other Specialties Pulmonary Disease
  • Location New York, NY
  • Active Since 12/15/2006
  • Last Updated 06/27/2023
  • Taxonomy Code 207RC0200X
  • Entity Type Individual
  • NPI Number 1073675005

Products in Payments

  • Otezla (Drug) $17,325
  • ZYVOX (Drug) $15,083
  • Procalcitonin (Drug) $12,662
  • Veklury (Drug) $10,394
  • ZERBAXA (Drug) $9,249
  • PNEUMOVAX 23 (Biological) $6,226
  • Procalcitonin (Device) $6,171
  • ACCELERATE PHENO (Device) $4,310
  • Baxdela (Drug) $3,933
  • BRAHMS PCT KRYPTOR (Device) $2,000
  • Fetroja (Drug) $1,800
  • TALTZ (Drug) $1,050
  • NephroCheck Test (Device) $99.36
  • NUZYRA (Drug) $94.83
  • STIOLTO RESPIMAT (Drug) $90.51
  • ACCELERATE PHENOTEST BC KIT (Device) $78.13
  • Reagent (Device) $72.87
  • PREVYMIS (Drug) $49.09
  • ImmunoCAP (Device) $30.29
  • TRELEGY ELLIPTA (Drug) $21.71

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Critical Care Medicine Doctors in New York

Dr. Lonny Yarmus, D.o, D.O

Critical Care Medicine — Payments: $1.0M

Critical Care Medicine $1.0M

Dr. Charles Powell, M.d, M.D

Critical Care Medicine — Payments: $611,991

Critical Care Medicine $611,991

Maria Padilla, Md, MD

Critical Care Medicine — Payments: $135,278

Critical Care Medicine $135,278

Dr. Ani Nalbandian, M.d, M.D

Critical Care Medicine — Payments: $100,000

Critical Care Medicine $100,000

Dr. James Horowitz, M.d, M.D

Critical Care Medicine — Payments: $87,935

Critical Care Medicine $87,935

Dr. Bushra Mina, M.d, M.D

Critical Care Medicine — Payments: $80,732

Critical Care Medicine $80,732